接受恩杂鲁胺治疗的晚期尿路上皮癌患者的临床结局：日本一项回顾性多中心研究 - Suppr | 超能文献

相似文献

1

Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.接受恩杂鲁胺治疗的晚期尿路上皮癌患者的临床结局：日本一项回顾性多中心研究

Int J Urol. 2024 Jun;31(6):696-698. doi: 10.1111/iju.15435. Epub 2024 Feb 29.

2

Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review.恩杂鲁胺治疗转移性尿路上皮癌时皮肤不良反应的特征：一项回顾性研究。

J Am Acad Dermatol. 2024 Oct;91(4):753-755. doi: 10.1016/j.jaad.2024.06.037. Epub 2024 Jun 21.

3

Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.外周神经病变和神经电生理变化与晚期尿路上皮癌患者的恩福妥单抗 vedotin：一项前瞻性多中心队列研究。

Int J Clin Oncol. 2024 May;29(5):602-611. doi: 10.1007/s10147-024-02481-8. Epub 2024 Feb 28.

4

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.恩杂鲁胺和帕博利珠单抗在晚期尿路上皮癌患者中的临床应用：基于治疗标准运用临床判断

ESMO Open. 2024 Sep;9(9):103725. doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.

5

Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.关于：EV-301长期结果：恩杂鲁胺与化疗用于既往治疗过的晚期尿路上皮癌患者的III期试验的24个月结果

Eur Urol. 2024 Aug;86(2):183-184. doi: 10.1016/j.eururo.2024.03.011. Epub 2024 Mar 26.

6

Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺与帕博利珠单抗用于未经治疗的晚期尿路上皮癌

Eur Urol. 2024 Sep;86(3):280-281. doi: 10.1016/j.eururo.2024.03.029. Epub 2024 Apr 9.

7

Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌

Eur Urol. 2024 Sep;86(3):282-283. doi: 10.1016/j.eururo.2024.03.032. Epub 2024 Apr 16.

8

Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌

Eur Urol. 2024 Sep;86(3):283. doi: 10.1016/j.eururo.2024.05.001. Epub 2024 May 13.

9

Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.p53 和 FGFR3 的免疫组化表达预测转移性尿路上皮癌对恩福替尼治疗的反应。

Int J Mol Sci. 2024 Sep 26;25(19):10348. doi: 10.3390/ijms251910348.

10

Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?恩福妥单抗和帕博利珠单抗联合治疗在尿路上皮癌中的相关变革：还有什么遗留问题？

Med. 2024 Jun 14;5(6):490-492. doi: 10.1016/j.medj.2024.04.006.

引用本文的文献

1

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.改良型恩杂鲁胺（enfortumab vedotin）不适宜标准（mEVITA）在晚期尿路上皮癌中的疗效

Sci Rep. 2025 Jul 18;15(1):26127. doi: 10.1038/s41598-025-09806-1.

2

Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.恩诺单抗治疗相关皮肤反应作为生存和治疗反应的替代标志物

Int J Clin Oncol. 2025 Feb;30(2):267-276. doi: 10.1007/s10147-024-02672-3. Epub 2024 Dec 16.

3

Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.